

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5656884

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	NUNC PRO TUNC ASSIGNMENT
EFFECTIVE DATE:	09/16/2016
CONVEYING PARTY DATA	
Name	Execution Date
INSTITUT DE RECHERCHES CLINIQUES DE MONTRÉAL	07/24/2019
RECEIVING PARTY DATA	
Name:	LCB PHARMA INC.
Street Address:	12230 LEMESURIER
City:	MONTREAL
State/Country:	CANADA
Postal Code:	H4K 2B3
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16333833
CORRESPONDENCE DATA	
Fax Number:	(514)397-4382
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(514)397-5119
Email:	afovero@lavery.ca
Correspondent Name:	LAVERY, DE BILLY LLP
Address Line 1:	1 PLACE VILLE MARIE, SUITE 4000
Address Line 4:	MONTREAL, QUEBEC H3B 4M4
ATTORNEY DOCKET NUMBER:	G16112-00020-IP
NAME OF SUBMITTER:	ANNA FOVERO
SIGNATURE:	/ANNA FOVERO/
DATE SIGNED:	08/07/2019
Total Attachments: 3	
source=Cession universelle IRCM to LCB Pharma signee#page1.tif	
source=Cession universelle IRCM to LCB Pharma signee#page2.tif	
source=Cession universelle IRCM to LCB Pharma signee#page3.tif	

CONFIRMATION OF PAST ASSIGNMENT AND ASSIGNMENT OF INVENTION

UNIVERSAL

WHEREAS, the invention entitled NUCLEOSIDE ANALOGUES AND METHODS OF USE THEREOF described in International Application No. PCT/CA2017/051096 filed September 18, 2017 claiming priorities on US Patent Application No. 62/395,401 filed on September 16, 2016; US Patent Application No. 62/395,411 filed on September 16, 2016; and US Patent Application No. 62/395,430 filed on September 16, 2016; and which was nationalized in the USA under the number 16/333,833, or a part of said invention, was assigned on June 14, 2017 (hereinafter referred to as the "past assignment") by INSTITUT DE RECHERCHES CLINIQUES DE MONTREAL (IRCM), whose full address is 110, avenue des Pins Ouest, Montréal, Québec CANADA H2W 1R7 (hereinafter referred to as the Assignor) to LCB PHARMA INC., whose full post office address is 12230, avenue Lemesurier, Montréal, Québec, CANADA H4K 2B3 (hereinafter referred to as the Assignee);

WHEREAS the Assignor and the Assignee are desirous of confirming this past assignment; and

WHEREAS the Assignor is desirous of assigning and the Assignee is desirous of obtaining any part of said invention not previously assigned.

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Assignor has, and by these present do hereby sell, assign and transfer unto said Assignee, its successors and assigns, the Assignor's entire right, title and interest in and to said part of said invention not previously assigned as described in the aforesaid application, in any form or embodiment thereof, and in and to the aforesaid application; and in and to any applications based thereon filed in any foreign country, including the right to file said foreign

applications under the provisions of the Patent Cooperation Treaty and under the Paris Convention; also the Assignor's entire right, title and interest in and to any and all patents, reissues or extensions thereof to be obtained in this or any foreign country upon said invention or inventions and any divisional, continuation, continuation-in-part, substitute application(s) or supplementary disclosure(s) which may be filed upon said invention or inventions, in any country; and the Assignor hereby authorizes and requests the issuing authority to issue any and all patents on said application or applications to said Assignee.

The Assignors further agrees, without any payment by said Assignee other than expenses incurred by the undersigned, to communicate to said Assignee, its representatives or agents, any facts useful as evidence for interference purposes or for other proceedings relating to intellectual property encompassing the invention, whenever requested; testify in any interference, litigation or other proceedings, whenever requested; and execute and deliver, on request, all lawful papers required to make any of the foregoing provisions effective, and likewise make these provisions binding upon the Assignor's heirs, legal representatives, administrators and assigns.

Les soussignés désirent que la présente cession soit rédigée en anglais. The undersigned request that the present assignment be drafted in English.

IN WITNESS WHEREOF, the Assignors and Assignee have hereunto set their hands and seal.

WITNESS

DATE

ASSIGNOR

[Signature]
Signature of Witness

24/7/2019
MM/DD/YYYY

[Signature]
Signature of authorized representative of
INSTITUT DE RECHERCHES
CLINIQUES DE MONTREAL

Paiman Shooshtarizadeh, Ph. D.
Conseiller, transfert de technologies
Technology Transfer Officer
Name of Witness

Paul Robert
Name of authorized representative of
INSTITUT DE RECHERCHES CLINIQUES
DE MONTREAL

Vt. legal-affaire
Title of authorized representative of
INSTITUT DE RECHERCHES CLINIQUES
DE MONTREAL

WITNESS

DATE

ASSIGNEE

[Signature]
Signature of Witness

07/24/2019
MM/DD/YYYY

[Signature]
Signature of authorized representative
of LCB PARMA INC.

LUCILE LOFLEUR
Name of Witness

Yvan Guindon
Name of authorized representative of
LCB PHARMA INC.

PRESIDENT
Title of authorized representative of
LCB PHARMA INC.

The Assignment is executed *nunc pro tunc* as of September 16, 2016.